In brief
- Ceruvia Lifesciences has raised $8 million to fully fund an integrated phase 1 and 2 clinical trial for BOL-148.
- BOL-148 is an LSD analog described by the company as non-hallucinogenic, with its therapeutic potential still under investigation.
- The August 3 release forecast a German trial application in September 2026 and initial data in the second quarter of 2027; this review does not confirm progress against that timetable.
The US-based company Ceruvia Lifesciences announced on August 3 that it has secured the $8 million needed to complete an integrated phase 1 and 2 clinical trial for BOL-148, a molecule related to LSD but engineered to avoid its psychedelic effects. The target condition is cluster headache, one of the most intense neurological pain disorders known.
One atom of difference
BOL-148, which the company also identifies as NYPRG-101, is 2-bromo-LSD: the same structure as LSD with a bromine atom added at a specific position. This minimal change is sufficient to suppress hallucinogenic activity without eliminating other effects on the nervous system—a property known since the early decades of lysergic derivative research that is now being leveraged for clinical purposes.
The program is supported by two precedents cited by the company: preliminary clinical observations from a study conducted at Harvard Medical School, where patients with chronic cluster headache achieved a complete and lasting response, and a previous phase 1 safety study conducted by the company in healthy volunteers.
Trial design
The study design combines two stages into a single trial. The first part is a classic phase 1 single ascending dose study in healthy adults. The second is a randomized, placebo-controlled phase 2 study in people with cluster headaches, designed to assess both safety and efficacy while exploring dose-response relationships and the duration of the effect. Ceruvia expects to submit the clinical trial application in Germany in September 2026, enroll the first participant in the final quarter of the year, and obtain preliminary phase 1 data in the second quarter of 2027. The results would be used to design a pivotal phase 3 trial in the United States and the European Union.
“By committing the capital necessary to complete this integrated phase 1/2 study, we are in a position to evaluate both the safety and the therapeutic potential of BOL-148 within a single clinical trial,” said Carey Turnbull, founder and CEO of the company, which was established in 2017.
What this implies
This announcement should be read for what it is: a funding round and a timeline, not a clinical result. The current backing for the molecule comes from a pilot study with a small number of patients and a phase 1 safety study; the release gives no results from the randomized trial, and this review does not establish its current recruitment status. Cluster headache, nicknamed “suicide headache” due to its intensity, lacks FDA-approved preventive treatments for its chronic forms, according to the release, which explains the interest in any new pathway.
BOL-148 explores an analog described as non-hallucinogenic. Other psychedelic research programs like the pharmaceutical LSD DT120, have their own designs and objectives. The announced BOL-148 funding supports investigation but does not establish efficacy or successful separation of clinical benefit from subjective effects.
Source
- Ceruvia Lifesciences. Ceruvia Raises $8 Million to Complete Integrated Phase 1/2 Trial of Proprietary Non-Hallucinogenic LSD Analog for Cluster Headache. BioSpace / PR Newswire, August 3, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
